论文部分内容阅读
目的观察长期家庭氧疗联合吸入舒利迭(沙美特罗替卡松)对COPD稳定期患者肺功能的影响,评价其能否达到阻止或延缓肺功能进行性下降、提高生存质量、延长生存期。方法将新郑市中医院87例中重度慢性阻塞性肺疾病患者随机分成两组,两组患者均接受常规治疗,此外观察组给予家庭氧疗联合吸入舒利迭,为期6个月,评估两组治疗前、治疗3个月、6个月时肺功能、临床症状评分、呼吸困难程度变化、活动能力、急性发作次数及不良反应。结果疗程中有7例退出试验,其余80例患者均完成试验,试验前对照组、观察组用力肺活量(FVC)、第1min用力呼气容积(FEV1)、最大肺活量(MVV)比较差异无统计学意义(P>0.05),观察组COPD患者长期氧疗联合吸入舒利迭3个月后FVC、FEV1、MVV明显提高,而对照组无变化,6个月后FVC、FEV1、MVV均有改善,症状低于对照组。观察组6个月后肺功能虽无改善但对照组肺功能明显下降。结论舒利迭联合长期家庭氧疗可缓解慢性阻塞性肺疾病稳定期肺功能进行性恶化同时气急缓解,症状减轻,活动范围扩大。
Objective To observe the effect of long-term home oxygen therapy combined with inhaled seretide (salmeterol) on pulmonary function in patients with stable COPD and evaluate whether it can prevent or delay the progressive decline of pulmonary function, improve the quality of life and prolong the survival period . Methods 87 cases of patients with moderate-severe chronic obstructive pulmonary disease in Xinzheng Hospital of Traditional Chinese Medicine were randomly divided into two groups. Both groups received routine treatment. In addition, the observation group received home oxygen therapy combined with inhaled seretide for 6 months. Before treatment, 3 months and 6 months after treatment, lung function, clinical symptom scores, changes in degree of dyspnea, activity ability, number of acute attacks and adverse reactions. Results During the course of treatment, 7 patients were withdrawn from the test and the remaining 80 patients completed the test. Before the test, the FVC, FEV1 and MVV in the control group, the observation group were not statistically different (P> 0.05). The FVC, FEV1 and MVV in long-term oxygen therapy and long-term oxygen therapy combined with seretide in observation group were significantly higher than those in control group, and the changes of FVC, FEV1 and MVV were all improved after 6 months in COPD patients. Symptoms lower than the control group. Six months after the observation group, pulmonary function did not improve, but the control group, pulmonary function decreased significantly. Conclusion Combined with long-term home oxygen therapy, Seretide can alleviate the progressive worsening of pulmonary function in patients with chronic obstructive pulmonary disease and relieve the symptoms of acute respiratory distress syndrome.